Pharmacological modulation of vascular inflammation: In atherothrombosis

Annals of the New York Academy of Sciences

Volumn 1207, Issue , 2010, Pages 23-31

  De Caterina, Raffaele ^a,b   Massaro, Marika ^c   Scoditti, Egeria ^c   Carluccio, Maria Annunziata ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Dipyridamole; Endothelial activation; Endothelial cells; Inflammation; Nuclear factor B

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; AUTACOID;

ARTICLE; ATHEROSCLEROSIS; ATHEROTHROMBOSIS; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN FUNCTION; RISK FACTOR; VASCULAR DISEASE; VASCULITIS; BIOLOGICAL MODEL; BLOOD; DRUG EFFECT; ENDOTHELIUM; HEART INFARCTION; PATHOPHYSIOLOGY; REVIEW; THROMBOSIS;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIPYRIDAMOLE; ENDOTHELIUM; HUMANS; INFLAMMATION MEDIATORS; MODELS, CARDIOVASCULAR; MYOCARDIAL INFARCTION; THROMBOSIS; VASCULITIS;

EID: 78149258162     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05784.x     Document Type: Article

References (78)

1. Fry,D.L. 1968.Acute vascular endothelial changes associated with increased blood velocity gradients. Circ. Res. 22: 165- 197.
2. Fry, D.L. 1969. Certain histological and chemical responses of the vascular interface to acutely induced mechanical stress in the aorta of the dog. Circ. Res. 24: 93-108.
3. Wright, H.P. 1971. Areas ofmitosis in aortic endothelium of guinea-pigs. J. Pathol. 105: 65-67.
4. Gofman, J.W. & F. Lindgren. 1950. The role of lipids and lipoproteins in atherosclerosis. Science 111: 166-171.
5. Musliner, T.A., C. Giotas & R.M. Krauss. 1986. Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects. Arteriosclerosis 6: 79-87.
6. Rudel, L.L., J.S. Parks, F.L. Johnson & J. Babiak. 1986. Low density lipoproteins in atherosclerosis. J. Lipid Res. 27: 465-474.
7. Baroldi, G. 1965. Acute coronary occlusion as a cause of myocardial infarct and sudden coronary heart death. Am. J. Cardiol. 16: 859-880.
8. Roberts,W.C. & L.M. Buja. 1972. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction: a study of 107 necropsy patients. Am. J. Med. 52: 425-443.
9. Roberts, W. 1974. Editorial: coronary thrombosis and fatal myocardial ischemia. Circulation 49: 1-3.
10. DeWood, M.A., J. Spores, R. Notske, et al. 1980. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 303: 897-902.
11. Davies, M.J. & A.C. Thomas. 1985. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br. Heart J. 53: 363-373.
12. Ganz,W., I. Geft,P.K. Shah, et al. 1984. Intravenous streptokinase in evolving acutemyocardial infarction.Am. J. Cardiol. 53: 1209-1216.
13. Lewis, H.D. Jr., J.W. Davis, D.G. Archibald, et al. 1983. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N. Engl. J.Med. 309: 396-403.
14. Serruys, P.W., W. Wijns, M. Van Den Brand, et al. 1983. Is transluminal coronary angioplasty mandatory after successful thrombolysis? Quantitative coronary angiographic study. Br. Heart J. 50: 257-265.
15. Spann, J.F., S. Sherry, B.A. Carabello, et al. 1982. High-dose, brief intravenous streptokinase early in acute myocardial infarction. Am. Heart J. 104: 939-945.
16. Terrosu, P.,G.V. Ibba, G.M.Contini&V. Franceschino. 1984. Angiographic features of the coronary arteries during intracoronary thrombolysis. Br. Heart J. 52: 154-163.
17. Timmis, G.C., V. Gangadharan, A.M. Hauser, et al. 1982. Intracoronary streptokinase in clinical practice. Am. Heart J. 104: 925-938.
18. Weinstein, J. 1982. Treatment of myocardial infarction with intracoronary streptokinase: efficacy and safety data from 209 United States cases in the Hoechst-Roussel registry. Am. Heart J. 104: 894-898.
19. Baigent, C., R. Collins, P. Appleby, et al. 1998. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 316: 1337-1343.
20. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 1988. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acutemyocardial infarction: ISIS-2. J. Am. Coll. Cardiol. 12: 3A-13A.
21. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 1988. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acutemyocardial infarction: ISIS-2. Lancet 2: 349-360.
22. Boissel, J.P. 1988. The ISIS-2 study (International Study of Infarction Survival). Rev. Prat. 38: 1285-1288.
23. Fresco, C., M.G. Franzosi, A.P. Maggioni & G. Tognoni. 1990. The GISSI-2 trial: premises, results, epidemiological (and other) implications. Clin. Cardiol. 13: VIII32-36.
24. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. 1990. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336: 65-71.
25. Hennekens, C.H. 1994. Thrombolytic therapy: pre- and post-GISSI-2, ISIS-3, and GUSTO-1. Clin. Cardiol. 17: I15-I17.
26. Gerrity, R.G. 1981. The role of the monocyte in atherogenesis. II.Migration of foam cells from atherosclerotic lesions. Am. J. Pathol. 103: 191-200.
27. Joris, I., T. Zand, J.J. Nunnari, et al. 1983. Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am. J. Pathol. 113: 341-358.
28. Faggiotto, A., R. Ross & L. Harker. 1984. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 4: 323-340.
29. Stary, H.C. 1987.Macrophages, macrophage foam cells, and eccentric intimal thickening in the coronary arteries of young children. Atherosclerosis 64: 91-108.
30. Rosenfeld, M.E., T. Tsukada, A.M. Gown & R. Ross. 1987. Fatty streak initiation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 7: 9-23.
31. Clinton, S.K., R. Underwood, L. Hayes, et al. 1992. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am. J. Pathol. 140: 301-316.
32. Libby, P. & P. Theroux. 2005. Pathophysiology of coronary artery disease. Circulation 111: 3481-3488.
33. Annex, B.H., S.M. Denning, K.M. Channon, et al. 1995. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 91: 619-622.
34. Geng, Y.J., Q. Wu, M. Muszynski, et al. 1996. Apoptosis of vascular smoothmuscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler. Thromb. Vasc. Biol. 16: 19- 27.
35. Thyberg, J. 1996. Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int. Rev. Cytol. 169: 183-265.
36. Newby, A.C. 1997. Molecular and cell biology of native coronary and vein-graft atherosclerosis: regulation of plaque stability and vessel-wall remodelling by growth factors and cell-extracellular matrix interactions. Coron. Artery Dis. 8: 213-224.
37. Peoples, G.E., S. Blotnick, K. Takahashi, et al. 1995. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factorlike growth factor and basic fibroblast growth factor: a potential pathologic role. Proc. Natl. Acad. Sci. USA 92: 6547-6551.
38. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
39. Hansson, G.K., P. Libby, U. Schonbeck & Z.Q. Yan. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91: 281-291.
40. Packard, R.R. & P. Libby. 2008. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 54: 24-38.
41. De Caterina, R., M. Massaro & P. Libby. 2007. Endothelial functions and dysfunctions. In Endothelial Dysfunctions in Vascular Disease. De Caterina, R. & P. Libby, Eds.: 3-25. Blackwell-Futura. New York.
42. De Caterina, R. 1999. Inflammation and early events in atherogenesis. Cardiologia 44(Suppl 1): 109-115.
43. De Caterina, R., A. Zampolli, G. Lazzerini & P. Libby. 2007. Endothelial activation and the initiation of atherosclerosis. In EndothelialDysfunctions in VascularDisease.De Caterina, R. & P. Libby, Eds.: 26-35. Blackwell-Futura. New York.
44. De Caterina, R., A. Zampolli, S. Del Turco & P. Libby. 2007. Mechanisms of plaque progression and complications. In Endothelial Dysfunctions in Vascular Disease. De Caterina, R. & P. Libby, Eds.: 36-54. Blackwell-Futura. New York.
45. Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985; 5: 293-302.
46. Gimbrone, M.A., Jr., T. Nagel, J.N. Topper. 1997. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J. Clin. Invest. 99: 1809-1813.
47. Davies, P.F. 1995. Flow-mediated endothelial mechanotransduction. Physiol. Rev. 75: 519-560.
48. Ando, J., H. Tsuboi, R. Korenaga, et al. 1994. Shear stress inhibits adhesion of cultured mouse endothelial cells to lymphocytes by downregulating VCAM-1 expression. Am. J. Physiol. 267: C679-C687.
49. DeCaterinaR,LibbyP, PengHB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 1995; 96: 60-68.
50. Khan, B.V., D.G. Harrison, M.T. Olbrych, et al. 1996. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc. Natl. Acad. Sci. USA 93: 9114-9119.
51. Bochner, B.S., F.W. Luscinskas, M.A. Jr. Gimbrone, et al. 1991. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J. Exp. Med. 173: 1553-1557.
52. Cybulsky, M.I., J.W. Fries, A.J. Williams, et al. 1991. Alternative splicing of human VCAM-1 in activated vascular endothelium. Am. J. Pathol. 138: 815-820.
53. Nagel, T., N. Resnick,W.J. Atkinson, C.F. Jr. Dewey & M.A., Jr.Gimbrone. 1994. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J. Clin. Invest. 94: 885-891.
54. Resnick, N., T. Collins, W. Atkinson, et al. 1993. Plateletderived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc. Natl. Acad. Sci. USA 90: 4591-4595.
55. Libby, P. 2008. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am. .J Med. 121: S21-S31.
56. Collins, T. 1993. Endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab. Invest. 68: 499-508.
57. Ridker, P.M., N. Rifai, M. Clearfield, et al. 2001. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344: 1959-1965.
58. Ridker, P.M., C.P.Cannon,D.Morrow, et al. 2005. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352: 20-28.
59. Koenig, W., H. Lowel, J. Baumert & C. Meisinger. 2004. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109: 1349-1353.
60. Zacho, J., A. Tybjaerg-Hansen, J.S. Jensen, et al. 2008. Genetically elevated C-reactive protein and ischemic vascular disease.N. Engl. J. Med. 359: 1897-1908.
61. Schonbeck, U. & P. Libby. 2001. CD40 signaling and plaque instability. Circ. Res. 89: 1092-1103.
62. Patel, D.A., S.R. Srinivasan, J.H. Xu, et al. 2006. Adiponectin andits correlates of cardiovascular risk inyoung adults: the Bogalusa Heart Study. Metabolism 55: 1551-1557.
63. Skurk, T., H. Kolb, S. Muller-Scholze, et al. 2005. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur. J. Endocrinol. 152: 863-868.
64. Inokubo, Y., H. Hanada, H. Ishizaka, et al. 2001. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 141: 211-217.
65. Mallat, Z. & A. Tedgui. 2001. Current perspective on the role of apoptosis in atherothrombotic disease. Circ. Res. 88: 998-1003.
66. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. 2001. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357: 995-1001.
67. Ridker, P.M., N. Rifai, M. Pfeffer, et al. 2000. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events aftermyocardial infarction. Circulation 101: 2149-2153.
68. Ridker, P.M., N. Rifai, M.J. Stampfer & C.H. Hennekens. 2000. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767-1772.
69. Albert,M.A., E. Danielson, N. Rifai & P.M. Ridker. 2001. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64-70.
70. Wissen, S., M.D. Trip, T.J. Smilde, et al. 2002. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165: 361-366.
71. Ree, M.A.,M.V. Huisman, H.M. Princen, et al. 2003. Strong decrease of high sensitivity C-reactive protein with highdose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166: 129-135.
72. Nissen, S.E., E.M. Tuzcu, P. Schoenhagen, et al. 2004. Effect of intensive comparedwith moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 1071-1080.
73. De Caterina R. & C.Manes. Inflammation in early atherogenesis: impact ofACE inhibition. Eur. Heart J. 2003:A15-A24.
74. Graham, I.,D. Atar, K. Borch-Johnsen, et al. 2007. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 28: 2375-2414.
75. Mann, D.L., J.J. McMurray, M. Packer, et al. 2004. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized EtanerceptWorldwide Evaluation (RENEWAL). Circulation 109: 1594-1602.
76. Crossman, D.C., A.C. Morton, J.P. Gunn, et al. 2008. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 9: 8.
77. Tardif, J.C., J.J. McMurray, E. Klug, et al. 2008. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371: 1761-1768.
78. Albers, G.W., P. Amarenco, J.D. Easton, et al. 2008. Antithrombotic and thrombolytic therapy for ischemic stroke: AmericanCollege ofChest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 630S-669S.